PIRS stock forecast
Our latest prediction for Pieris Pharmaceuticals, Inc.'s stock price was made on the Sept. 6, 2019 when the stock price was at 4.45$.
In the short term (2weeks), PIRS's stock price should underperform the market by -0.48%. During that period the price should oscillate between -10.21% and +10.61%.
In the medium term (3months), PIRS's stock price should outperform the market by 1.29%. During that period the price should oscillate between -21.49% and +32.12%.Get email alerts
Create a solid portfolio with PIRS
About Pieris Pharmaceuticals, Inc.
Pieris Pharmaceuticals, Inc. is a clinical-stage biotechnology company, which engages in the discovery and development of Anticalin-based drugs. Its pipeline includes immuno-oncology, respiratory, and anemia and other disease areas. The company was founded by Claus Schalper and Arne Skerra in 2001 and is headquartered in Boston, MA.
At the moment the company generates 27M USD in revenues.
On its last earning announcement, the company reported a loss of -0.77$ per share.
The book value per share is 1.02$
Three months stock forecastSept. 6, 2019
|Revenue USD||Gross Margin||Operating Income||Operating Margin||Net Income||Earnings Per Share||Dividends||Payout Ratio||Shares||Book Value Per Share||Operating Cash Flow||Cap Spending||Free Cash Flow|